Corvus Pharmaceuticals, Inc. $CRVS Position Lifted by GSA Capital Partners LLP

GSA Capital Partners LLP grew its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 25.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 401,407 shares of the company’s stock after purchasing an additional 82,675 shares during the quarter. Corvus Pharmaceuticals makes up about 0.2% of GSA Capital Partners LLP’s holdings, making the stock its 25th largest position. GSA Capital Partners LLP’s holdings in Corvus Pharmaceuticals were worth $2,958,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey acquired a new position in Corvus Pharmaceuticals in the second quarter worth about $49,000. Sender Co & Partners Inc. acquired a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at approximately $52,000. ProShare Advisors LLC bought a new position in Corvus Pharmaceuticals during the second quarter worth $54,000. China Universal Asset Management Co. Ltd. boosted its holdings in Corvus Pharmaceuticals by 20.2% in the second quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company’s stock worth $62,000 after purchasing an additional 2,599 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in Corvus Pharmaceuticals during the second quarter valued at $70,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock opened at $18.66 on Tuesday. Corvus Pharmaceuticals, Inc. has a 12-month low of $2.54 and a 12-month high of $26.95. The stock has a market capitalization of $1.56 billion, a PE ratio of -35.21 and a beta of 0.72. The firm has a 50 day simple moving average of $12.93 and a 200-day simple moving average of $8.96.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright upped their price objective on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Jefferies Financial Group raised their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Oppenheimer increased their price objective on shares of Corvus Pharmaceuticals from $15.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Thursday, December 11th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.80.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.